BIOC - Biocept, Inc.
0.7683 +0.01 (1.31%)
After hours: 5:27PM EDT
| Previous Close | 0.7515 |
| Open | 0.7450 |
| Bid | 0.7500 x 1100 |
| Ask | 0.7683 x 1200 |
| Day's Range | 0.7406 - 0.7700 |
| 52 Week Range | 0.6600 - 3.7200 |
| Volume | 197,016 |
| Avg. Volume | 360,789 |
| Market Cap | 17.457M |
| Beta (3Y Monthly) | 2.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6310 |
| Earnings Date | Nov 11, 2019 - Nov 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- Simply Wall St.
Why Biocept, Inc.'s (NASDAQ:BIOC) CEO Pay Matters To You
Mike Nall became the CEO of Biocept, Inc. (NASDAQ:BIOC) in 2013. This analysis aims first to contrast CEO compensation...
- PR Newswire
Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE
SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed journal article featuring analytical validation results demonstrating the high sensitivity of the Company's Target Selector™ testing for EGFR, BRAF, and KRAS mutations in plasma circulating tumor DNA (ctDNA).
- PR Newswire
Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection Platform
The patent provides intellectual property protection for the Company's Switch-Blocker technology, which is core to Biocept's Target Selector™ assays for molecular analysis using real-time PCR, Sanger sequencing and next-generation sequencing (NGS).
- PR Newswire
Biocept to Present at Two Investment Conferences in September
SAN DIEGO , Sept. 3, 2019 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...
- PR Newswire
High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer
Data highlight the ability of Biocept's patented and proprietary circulating tumor DNA assays to consistently detect actionable biomarkers from the blood of patients diagnosed with lung cancer at a mutant ...
- PR Newswire
Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells
New patents further expand the Company's intellectual property estate for capturing and detecting rare cells of interest, including circulating tumor cells (CTCs), to aid in the management of patients ...
- PR Newswire
Biocept Reports Second Quarter 2019 Financial Results
- Second quarter 2019 revenues increased 45% and commercial samples increased 26% over the second quarter of 2018 - Revenues for the first six-month of 2019 increased 36% and commercial samples increased ...
- ACCESSWIRE
Biocept, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 12, 2019 / Biocept, Inc. (NASDAQ: BIOC ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 at 4:30 PM Eastern ...
- PR Newswire
Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019
SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...
- PR Newswire
Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®
SAN DIEGO, July 22, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into a Laboratory Services Provider Agreement with Beacon Laboratory Benefit Solutions, Inc. (BeaconLBS®), a nationally recognized premier provider of laboratory benefit management technology solutions to health and managed care companies in the United States. BeaconLBS administers laboratory benefit management programs for health plans to improve test ordering efficiency, test appropriateness, affordability, and quality of care for health plan members.
- Simply Wall St.
Does Biocept, Inc. (NASDAQ:BIOC) Have A High Beta?
Anyone researching Biocept, Inc. (NASDAQ:BIOC) might want to consider the historical volatility of the share price...
- PR Newswire
Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel
Biocept continues to expand its commercial offering for breast cancer and remains the only liquid biopsy provider to offer single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis ...
- PR Newswire
Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4
SAN DIEGO , June 3, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...
- PR Newswire
Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally
The patent encompasses the use of any biological sample type of interest and is the 33rd patent issued to Biocept that is core to its liquid biopsy technology and commercial testing platforms. "The granting of this patent further expands Biocept's international footprint for capturing and analyzing rare cells from biological fluids, such as blood, bone marrow, cerebral spinal fluid (CSF), and tissue, to assess the status of patients with cancer," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept.
- PR Newswire
Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer
Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO , May 20, 2019 /PRNewswire/ ...
- PR Newswire
Biocept Reports First Quarter 2019 Financial Results
- Revenues increased 27% compared to the first quarter of 2018 - Billable samples grew 7% year over year, and increased 23% vs. the fourth quarter of 2018 - Commercial gains driven primarily by broadened ...
- PR Newswire
Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019
SAN DIEGO , May 1, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information ...
- PR Newswire
Biocept Reports 2018 Fourth Quarter and Full Year Financial Results
Progress made implementing the Company's commercial strategy highlighted by 7% sequential quarterly growth in billable test volume in the fourth quarter of 2018 compared to the third quarter of 2018 Capitalized ...
- PR Newswire
Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment
Expansion of Biocept's EmpowerTC™ offering now includes predictive and prognostic biomarker testing to aid pathologists and urologists in the management of patients diagnosed with prostate cancer SAN DIEGO ...
- PR Newswire
Biocept to Release 2018 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2019
SAN DIEGO , March 21, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable ...
- PR Newswire
Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device
Biocept believes the newly granted patent has claims that encompass any biological sample type of interest, and is the 32nd patent issued to Biocept that is core to its liquid biopsy technology platforms. The technology covered by this issued patent combines Biocept's patented microchannel platform together with antibodies to enable the capture of rare cells of interest.
- ACCESSWIRE
Biocept, Potential Near-Term Catalysts for Biocept
NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
- PR Newswire
Biocept Announces Pricing of $8.2 Million Registered Direct Offering
SAN DIEGO, March 15, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $8.2 million of its common stock in a registered direct offering and warrants to purchase shares of Common Stock in a concurrent private placement. The combined purchase price for one share of common stock and each warrant will be $1.37. Under the terms of the purchase agreement, Biocept has agreed to sell approximately 5,950,000 shares of its common stock.
- PR Newswire
Biocept Expands its Pathology Partnership Offering for Liquid Biopsy with the Addition of Several Key Services
SAN DIEGO, March 13, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has expanded its pathology partnership platform, EmpowerTCTM, to now offer local pathologists the ability to analyze prognostic and predictive markers on CTCs from a liquid biopsy using immunocytochemistry (ICC) methods. This new offering, in addition to an expanded biomarker menu, supplements the previous capabilities of Biocept's proprietary pathology partnership platform to analyze liquid biopsy biomarkers using fluorescence in situ hybridization (FISH) methods.
